Biologics for Vision: 55.6% of denials overturned
In 9 California IMR decisions from 2020 to 2025, reviewers overturned 5 (55.6%). In the last five years: 57.1% of 7. 8 were medical-necessity disputes, 1 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 1 | 100.0% |
| 2022 | 1 | 100.0% |
| 2023 | 4 | 50.0% |
| 2025 | 1 | 0.0% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Prior therapies failedThe findings mention treatments that were tried without adequate response. | 3 | 33.3% | 55.6% |
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 3 | 0.0% | 55.6% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Tepezza. This patient has a history of active thyroid eye disease. The patient’s condition is causing a significant impact on daily activities and showing potential visual field compromise on visual field testing. Treatment with Tepezza is indicated for this patient with active …”
“Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Tepezza (teprotumumab-trbw) injections every three weeks for one year. In this case, the patient has a recurrence of his thyroid eye disease leading to optic neuropathy in the left eye, among other symptoms. The records noted a previous good response to treatment with Tepezza. Researchers report that …”
“Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Tepezza infusions beyond a lifetime total of eight infusions.Thyroid eye disease (TED) is a chronic immune-mediated inflammation of the orbit. It is the most common cause of unilateral and bilateral proptosis in adults. About 25 to 50% of Grave disease (GD) cases present with thyroid eye disease …”
And one the reviewer upheld
“The physician reviewer found that a patient has requested authorization and coverage for Tepezza (teprotumumab-trbw). In this case, the patient has requested retreatment following a completed initial course of Tepezza. The provider cites a study, which included a small retrospective cohort of eight patients who received a second course of Tepezza due to disease flare. Of these, only five achieved …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Biologics denials for Vision overturned?
In 9 California IMR decisions from 2020 to 2025, reviewers overturned 5 (55.6%). In the last five years: 57.1% of 7. 8 were medical-necessity disputes, 1 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.